Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Oct;98(1):71–77. doi: 10.1111/j.1365-2249.1994.tb06609.x

Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis.

K D Sekiyama 1, M Yoshiba 1, A W Thomson 1
PMCID: PMC1534161  PMID: 7923888

Abstract

Fulminant hepatic failure (FHF) is characterized by massive necroinflammation of the liver tissue and is associated with high mortality. Serum concentrations of IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-1 receptor antagonist (IL-1Ra) were measured in 30 patients with FHF and in 23 patients with acute hepatitis (AH) before start of treatment and in 23 healthy controls. Levels of all four molecules were increased significantly in FHF compared with AH, in which values were higher than in the healthy controls. High serum levels of IL-1 beta and a significantly reduced ratio of IL-1Ra to IL-1 beta (IL-1Ra/IL-1 beta) were observed in FHF patients who subsequently died compared with subjects who survived. TNF-alpha and IL-6 concentrations were correlated with levels of human hepatocyte growth factor (hHGF), an index of hepatocyte regeneration. Although serum cytokine levels varied considerably between patients within each group studied, it is suggested that the striking elevation in proinflammatory cytokine levels in FHF may reflect both the insufficiency of hepatitis virus elimination and a failure to control a vicious cytokine cascade leading to overwhelming hepatocyte destruction rather than regeneration. The high cytokine levels observed in these patients and the significantly elevated IL-1Ra/IL-1 beta ratio in FHF patients who survived compared with those who did not suggest the possible therapeutic use of cytokine antagonists for the control of this life-threatening disease.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akerman P., Cote P., Yang S. Q., McClain C., Nelson S., Bagby G. J., Diehl A. M. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol. 1992 Oct;263(4 Pt 1):G579–G585. doi: 10.1152/ajpgi.1992.263.4.G579. [DOI] [PubMed] [Google Scholar]
  2. Anastassakos C., Alexander G. J., Wolstencroft R. A., Avery J. A., Portmann B. C., Panayi G. S., Dumonde D. C., Eddleston A. L., Williams R. Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology. 1988 Apr;94(4):999–1005. doi: 10.1016/0016-5085(88)90559-8. [DOI] [PubMed] [Google Scholar]
  3. Andus T., Bauer J., Gerok W. Effects of cytokines on the liver. Hepatology. 1991 Feb;13(2):364–375. [PubMed] [Google Scholar]
  4. Arend W. P., Joslin F. G., Thompson R. C., Hannum C. H. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol. 1989 Sep 15;143(6):1851–1858. [PubMed] [Google Scholar]
  5. Arend W. P., Welgus H. G., Thompson R. C., Eisenberg S. P. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest. 1990 May;85(5):1694–1697. doi: 10.1172/JCI114622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Darlington G. J., Wilson D. R., Lachman L. B. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol. 1986 Sep;103(3):787–793. doi: 10.1083/jcb.103.3.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  8. Dinarello C. A., Thompson R. C. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today. 1991 Nov;12(11):404–410. doi: 10.1016/0167-5699(91)90142-G. [DOI] [PubMed] [Google Scholar]
  9. Dinarello C. A., Wolff S. M. The role of interleukin-1 in disease. N Engl J Med. 1993 Jan 14;328(2):106–113. doi: 10.1056/NEJM199301143280207. [DOI] [PubMed] [Google Scholar]
  10. Dudley F. J., Fox R. A., Sherlock S. Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet. 1972 Apr 1;1(7753):723–726. doi: 10.1016/s0140-6736(72)90234-6. [DOI] [PubMed] [Google Scholar]
  11. Feingold K. R., Soued M., Grunfeld C. Tumor necrosis factor stimulates DNA synthesis in the liver of intact rats. Biochem Biophys Res Commun. 1988 Jun 16;153(2):576–582. doi: 10.1016/s0006-291x(88)81134-3. [DOI] [PubMed] [Google Scholar]
  12. Fischer E., Marano M. A., Van Zee K. J., Rock C. S., Hawes A. S., Thompson W. A., DeForge L., Kenney J. S., Remick D. G., Bloedow D. C. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992 May;89(5):1551–1557. doi: 10.1172/JCI115748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fischer E., Van Zee K. J., Marano M. A., Rock C. S., Kenney J. S., Poutsiaka D. D., Dinarello C. A., Lowry S. F., Moldawer L. L. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 1992 May 1;79(9):2196–2200. [PubMed] [Google Scholar]
  14. Gohda E., Tsubouchi H., Nakayama H., Hirono S., Takahashi K., Koura M., Hashimoto S., Daikuhara Y. Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure. Exp Cell Res. 1986 Sep;166(1):139–150. doi: 10.1016/0014-4827(86)90514-8. [DOI] [PubMed] [Google Scholar]
  15. Granowitz E. V., Santos A. A., Poutsiaka D. D., Cannon J. G., Wilmore D. W., Wolff S. M., Dinarello C. A. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet. 1991 Dec 7;338(8780):1423–1424. doi: 10.1016/0140-6736(91)92725-h. [DOI] [PubMed] [Google Scholar]
  16. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Huggett A. C., Ford C. P., Thorgeirsson S. S. Effects of interleukin-6 on the growth of normal and transformed rat liver cells in culture. Growth Factors. 1989;2(1):83–89. doi: 10.3109/08977198909069084. [DOI] [PubMed] [Google Scholar]
  18. Ishiki Y., Ohnishi H., Muto Y., Matsumoto K., Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology. 1992 Nov;16(5):1227–1235. [PubMed] [Google Scholar]
  19. Kakumu S., Shinagawa T., Ishikawa T., Yoshioka K., Wakita T., Ito Y., Takayanagi M., Ida N. Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol. 1991 Dec;86(12):1804–1808. [PubMed] [Google Scholar]
  20. Kohase M., Henriksen-DeStefano D., May L. T., Vilcek J., Sehgal P. B. Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell. 1986 Jun 6;45(5):659–666. doi: 10.1016/0092-8674(86)90780-4. [DOI] [PubMed] [Google Scholar]
  21. Kuma S., Inaba M., Ogata H., Inaba K., Okumura T., Saito K., Yamamoto M., Ikehara S. Effect of human recombinant interleukin-6 on the proliferation of mouse hepatocytes in the primary culture. Immunobiology. 1990 Feb;180(2-3):235–242. doi: 10.1016/s0171-2985(11)80331-1. [DOI] [PubMed] [Google Scholar]
  22. McIntyre K. W., Stepan G. J., Kolinsky K. D., Benjamin W. R., Plocinski J. M., Kaffka K. L., Campen C. A., Chizzonite R. A., Kilian P. L. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991 Apr 1;173(4):931–939. doi: 10.1084/jem.173.4.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D., Möller A., Jacobsen H., Kirchner H. Antiviral effects of recombinant tumour necrosis factor in vitro. 1986 Oct 30-Nov 5Nature. 323(6091):816–819. doi: 10.1038/323816a0. [DOI] [PubMed] [Google Scholar]
  24. Nakamura T., Arakaki R., Ichihara A. Interleukin-1 beta is a potent growth inhibitor of adult rat hepatocytes in primary culture. Exp Cell Res. 1988 Dec;179(2):488–497. doi: 10.1016/0014-4827(88)90286-8. [DOI] [PubMed] [Google Scholar]
  25. Okamoto H., Okada S., Sugiyama Y., Tanaka T., Sugai Y., Akahane Y., Machida A., Mishiro S., Yoshizawa H., Miyakawa Y. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region. Jpn J Exp Med. 1990 Aug;60(4):215–222. [PubMed] [Google Scholar]
  26. Rakela J., Lange S. M., Ludwig J., Baldus W. P. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc. 1985 May;60(5):289–292. doi: 10.1016/s0025-6196(12)60534-5. [DOI] [PubMed] [Google Scholar]
  27. Sheron N., Lau J., Daniels H., Goka J., Eddleston A., Alexander G. J., Williams R. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol. 1991 Mar;12(2):241–245. doi: 10.1016/0168-8278(91)90945-8. [DOI] [PubMed] [Google Scholar]
  28. Strain A. J., Ismail T., Tsubouchi H., Arakaki N., Hishida T., Kitamura N., Daikuhara Y., McMaster P. Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest. 1991 May;87(5):1853–1857. doi: 10.1172/JCI115207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tilg H., Vogel W., Wiedermann C. J., Shapiro L., Herold M., Judmaier G., Dinarello C. A. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology. 1993 Nov;18(5):1132–1138. [PubMed] [Google Scholar]
  30. Trey C., Davidson C. S. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–298. [PubMed] [Google Scholar]
  31. Tsubouchi H., Niitani Y., Hirono S., Nakayama H., Gohda E., Arakaki N., Sakiyama O., Takahashi K., Kimoto M., Kawakami S. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology. 1991 Jan;13(1):1–5. [PubMed] [Google Scholar]
  32. Van Damme J., De Ley M., Opdenakker G., Billiau A., De Somer P., Van Beeumen J. Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature. 1985 Mar 21;314(6008):266–268. doi: 10.1038/314266a0. [DOI] [PubMed] [Google Scholar]
  33. Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C., Dinarello C. A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 1;5(3):338–343. doi: 10.1096/fasebj.5.3.1825816. [DOI] [PubMed] [Google Scholar]
  34. Warren R. S., Starnes H. F., Jr, Alcock N., Calvano S., Brennan M. F. Hormonal and metabolic response to recombinant human tumor necrosis factor in rat: in vitro and in vivo. Am J Physiol. 1988 Aug;255(2 Pt 1):E206–E212. doi: 10.1152/ajpendo.1988.255.2.E206. [DOI] [PubMed] [Google Scholar]
  35. Wolf H. K., Michalopoulos G. K. Hepatocyte regeneration in acute fulminant and nonfulminant hepatitis: a study of proliferating cell nuclear antigen expression. Hepatology. 1992 Apr;15(4):707–713. doi: 10.1002/hep.1840150426. [DOI] [PubMed] [Google Scholar]
  36. Yoshiba M., Sekiyama K., Iwamura Y., Sugata F. Development of reliable artificial liver support (ALS)--plasma exchange in combination with hemodiafiltration using high-performance membranes. Dig Dis Sci. 1993 Mar;38(3):469–476. doi: 10.1007/BF01316501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yoshioka K., Kakumu S., Arao M., Tsutsumi Y., Inoue M. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology. 1989 Nov;10(5):769–773. doi: 10.1002/hep.1840100504. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES